PDS Biotech up as cancer therapy hits efficacy milestone in mid-stage study

PDS Biotechnology

14/06/2023 11:50

** Shares of PDS Biotechnology Corp  PDSB.O  up 2.7% at
$6.81 premarket
    ** Co says threshold for efficacy achieved in mid-stage
study of therapy candidate PDS0101 in combination with Merck's
Keytruda in treating a type of head and neck cancer
    ** Threshold achieved when 14 out of the 54 enrolled
patients showed a confirmed objective response to treatment -
PDSB
    ** Efficacy and safety continue to be monitored as
additional patients have yet to undergo imaging evaluation -
PDSB
    ** Received guidance from FDA regarding a planned late-stage
study
    ** Co plans to submit an ammended application in Q3 seeking
the FDA's nod to begin the late-stage trial 
    ** Stock down 49.8% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))